Back to top

CONVERTIBLE PROMISSORY NOTE

Convertible Promissory Note

CONVERTIBLE PROMISSORY NOTE | Document Parties: DUSKA THERAPEUTICS, INC. | COMPANY OF AN OPINION OF COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE COMPANY THAT SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION IS IN COMPLIANCE WITH THE ACT OR UNLESS SOLD IN FULL COMPLIANCE WITH RULE 144 UNDER THE ACT. | Duska Therapeutics, Inc | ICON Capital Partners, LP You are currently viewing:
This Convertible Promissory Note involves

DUSKA THERAPEUTICS, INC. | COMPANY OF AN OPINION OF COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE COMPANY THAT SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION IS IN COMPLIANCE WITH THE ACT OR UNLESS SOLD IN FULL COMPLIANCE WITH RULE 144 UNDER THE ACT. | Duska Therapeutics, Inc | ICON Capital Partners, LP

. RealDealDocs™ contains millions of easily searchable legal documents and clauses from top law firms. Search for free - click here.
Title: CONVERTIBLE PROMISSORY NOTE
Governing Law: Pennsylvania     Date: 9/7/2007
Law Firm: Drinker Biddle    

CONVERTIBLE PROMISSORY NOTE, Parties: duska therapeutics  inc. , company of an opinion of counsel in form and substance satisfactory to the company that such offer  sale or transfer  pledge or hypothecation is in compliance with the act or unless sold in full compliance with rule 144 under the act. , duska therapeutics  inc , icon capital partners  lp
50 of the Top 250 law firms use our Products every day

Exhibit 10.1

NEITHER THIS NOTE NOR ANY OF THE SECURITIES ISSUABLE HEREUNDER HAS BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), AND MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF A REGISTRATION STATEMENT IN EFFECT WITH RESPECT TO THE SECURITIES, OR DELIVERY TO THE COMPANY OF AN OPINION OF COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE COMPANY THAT SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION IS IN COMPLIANCE WITH THE ACT OR UNLESS SOLD IN FULL COMPLIANCE WITH RULE 144 UNDER THE ACT.

CONVERTIBLE PROMISSORY NOTE

 

$100,000

  August 24, 2007

Duska Therapeutics, Inc. a Nevada Corporation whose address is Two Bala Plaza, Suite 300, Bala Cynwyd, Pennsylvania 19004 (the “ Company ”), for value received, hereby promises to pay to ICON Capital Partners, L.P. or their permitted assignees (each, a “ Holder ” and together, the “ Holders ”), the principal amount of One Hundred Thousand Dollars ($100,000) in accordance with the terms hereof.

1. Maturity . Except to the extent converted into Conversion Units (as defined below) pursuant to Section 3 hereof, the principal amount of this Promissory Note (this “ Note ”) shall be due and payable on November 24, 2007 (the “ Maturity Date ”).

2. Payments . Except in the event the Holders elect to convert the principal amount hereof pursuant to Section 3 hereof into Conversion Units pursuant to Section 3 hereof, those amounts shall be paid on the Maturity Date. All payments of principal and other amounts payable on or in respect of this Note or the indebtedness evidenced hereby shall be made to the Holders in U.S. dollars, by wire transfer, certified check or Company check. This Note may be prepaid by the Company, at any time, in whole or in part, from time to time, without penalty, at the principal amount hereunder. Payment of this Note shall not be secured by any of the Company’s assets.

3. Conversion . At the option of the Holders, upon the consummation of any equity or equity linked financing of the Company of at least $5,000,000 (the “ Offering ”), this Note shall be automatically converted into the units of common stock and warrants (the “ Conversion Units ”) being offered by the Company pursuant to the Offering (the “ Exchange ”). The number of Conversion Units to be issued upon conversion shall equal the principal being converted divided by the price per Conversion Unit in the Offering. The common stock and warrants comprising the Conversion Units shall have the same terms as those offered in the Offering. By electing to convert all or a portion of the principal balance of this Note into Conversion Units, each Holder shall be deemed to have irrevocably subscribed for Conversion Units. At any time prior to the Exchange, the principal amount of this Note can be fully converted into shares of the Company’s common stock, $.001 par value per share, by dividing the principal amount under the Note by $0.40, subject to adjustments as provided herein.

4. Warrant Coverage . Each Holder will receive, in the form attached hereto as Exhibit A , a warrant to purchase (the “ Warrant ”), in accordance with such Holder’s pro rata share, fully paid and nonassessable shares of common stock of the Company at a price equal to $0.40 (the “ Exercise Price ”) if exercised before August 24, 2012.

5. Registration Rights . In the event that the Company has not repaid this Note by the Maturity Date, the Company shall prepare promptly and file with the Securities and Exchange Commission (the “ SEC ”) as soon as practicable, but in no event later than the thirtieth (30 th ) day

 


following the Maturity Date (the “ Filing Date ”), a Registration Statement (the “ Registration Statement ”) on Form SB-2 (or, if Form SB-2 is not then available, on such form of Registration Statement as is then available) to effect a registration of all of the securities underlying the Warrants. The Company shall use its best efforts to cause the Registration Statement required to be filed pursuant to this Section to become effective as soon as practicable, but in no event later than the ninetieth (90 th ) day (or 120 days if such Registration Statement is reviewed by the SEC) following the Filing Date (the “ Registration Deadline ”). If the Registration Statement has not been declared effective by the Registration Deadline, the Company shall pay to the Holders an amount equal to 1.5% of the amount outstanding hereunder for each 30 day period beyond the Registration Deadline, provided that no more than $20,000 in such fees shall be payable .

6. Right of First Refusal . At any time while this Note remains outstanding, but in no event later than the date that is six months after the date hereof, subject to the terms and conditions specified in this Section 7, the Holders shall have a right to participate with respect to the issuance or possible issuance of any equity or equity-linked securities or debt which is convertible into equity or in which there is an equity component (as the case may be, “ Additional Securities ”) on the same terms and conditions as offered by the Company to the other purchasers of such Additional Securities. Each time the Company proposes to offer any Additional Securities, the Company shall make an offering of such Additional Securities to each Holder in accordance with the following provisions:

(1) At least 10 days prior to the issuance of any Additional Securities, the Company shall deliver a notice (the “ Issuance Notice ”) to each Holder stating (a) its bona fide intention to offer such Additional Securities, (b) the number of such Additional Securities to be offered, (c) the price and terms, if any, upon which it proposes to offer such Additional Securities, and (d) the anticipated closing date of the sale of such Additional Securities.

(2) By written notification received by the Company, within 10 business days after giving of the Issuance Notice, each Holder may elect to purchase or obtain, at the price and on the terms specified in the Issuance Notice, up to that number of such Additional Securities which equals such Holder’s Pro Rata Amount (as defined below). The “ Pro Rata Amount ” for such Holder shall equal that portion of the Additional Securities that the Company proposes to offer which equals the proportion that the number of shares of common stock that such Holder owns or has the right to acquire bears to the total number of shares of common stock then outstanding (assuming in each case the full conversion, exercise or exchange of all Convertible Securities and Purchase Rights then outstanding).

7. Covenants of the Company .

(a) The Company shall not, without the prior written consent of a majority in interest of the Holders (such consent not to be unreasonably withheld), incur or suffer to exist any new indebtedness for borrowed money that ranks senior to this Note.

(b) The Company shall not, without the prior approval of the Holders, create any sub-committee of the Board of Directors that is permitted to take action on behalf of the Company without the prior authorization and approval of the Board of Directors.

 

- 2 -

 


(c) Within 4 days following the execution of and delivery of this Note, the Company shall file with the Securities and Exchange Commission a statement on form 8-K (including the transaction documents of this financing as exhibits thereto) disclosing the details of this transaction.

8. Board Representation . Upon


 
SITE SEARCH

AGREEMENTS / CONTRACTS

Document Title:

Entire Document: (optional)

Governing Law:(optional)


Try our advanced search >>
 

CLAUSES

Search Contract Clauses >>

Browse Contract Clause Library>>

Get Email Updates
Email:
This is only a partial view of this document. We have millions of legal documents and clauses drafted by top law firms. learn more search for free browse for free learn more